NCT07358234
Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.
Enrolling by Invitation
EARLY_PHASE1Ages 18+InterventionalTreatmentMayo ClinicInvestigator-initiated
~60 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]budesonide oral suspension
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Esophageal diameter
Measured over from enrollment until up to 14 weeks
Conditions
Where it's being run
2 sites across 2 statesArizona1
Minnesota1
Study leadership
- Diana Snyder, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic
- Jennifer Horsley-Silva, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Esophageal diameterfrom enrollment until up to 14 weeks
the minimum esophageal diameter after 12 weeks of treatment.